Latest News and Press Releases
Want to stay updated on the latest news?
-
SANTA BARBARA, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) approved the Low...
-
SANTA BARBARA, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), announced today its participation at the William Blair 42nd Annual Growth Stock...
-
SANTA BARBARA, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), announced today its participation at the Virtual 19th Annual Craig-Hallum...
-
Record Growth Driven by Continued Expansion of Augmentation and Reconstruction Accounts Accelerated Gross Margin Improvement Through Execution of Commercial and Operational Plans SANTA BARBARA,...
-
SANTA BARBARA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of...
-
SANTA BARBARA, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of...
-
SANTA BARBARA, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of...
-
Sixth Consecutive Quarter of Record Growth Doubled Augmentation and Reconstruction Market Share Since 2019 Broadened Market Opportunity with Addition of Novel, FDA-Cleared Fat...
-
SANTA BARBARA, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of...
-
Estimates highest ever Breast Products yearly revenue of $80-$81 million representing 46%-47% full year growth Results driven by continued strong demand for Sientra Breast Products and commercial...